Hepatocellular carcinoma response to transarterial chemo-embolization is traditionally assessed by qualitative interpretation of imaging features and enhancement dynamics. However, quantitative parameters derived by fitting a dual-input single-compartment model on dynamic contrast-enhanced-MRI data show promise, as they may help discriminate non-viable from viable tumors after treatment. Peak enhancement ratio significantly decreased after transarterial chemo-embolization in tumors with complete response (i.e. non-viable tumor group). This pilot study suggests that quantitative dynamic contrast-enhanced-MRI parameters may be used to assess treatment response.